tti-621 for hematologic malignancies: a phase i dose escalation and expansion study
Published 3 years ago • 250 plays • Length 2:30Download video MP4
Download video MP3
Similar videos
-
2:24
first-in-human study of tti-621 in r/r hematologic malignancies
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
1:39
phase i/ii trial of adct-602 in b-all
-
5:18
upfront treatment in transplant candidates
-
1:53
the future of multiple myeloma treatment
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:47
limber-treg108: ck0804 add-on therapy in patients with mf with suboptimal response to ruxolitinib
-
0:35
tct 2021: what to look forward to
-
1:36
kt-333: a first-in-class stat3 degrader
-
1:14
highlights in quality management from ebmt
-
0:51
key unmet needs in the treatment of immune-mediated ttp